VivoSeq
Dermatology

Hidradenitis Suppurativa

83

Pipeline Programs↗

51

Active Trials↗

42

Companies Involved↗

Hidradenitis Suppurativa is a moderately active landscape with 83 programs across 42 companies. The most active players are Azora Therapeutics Australia Pty Ltd, Sonoma Biotherapeutics, Inc., Kymera Therapeutics, Inc.. 4 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

45/100

Mech. Concentration

9/100

Completion Rate

77/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Azora Therapeutics Australia Pty Ltd

1 program

Phase 1S

Sonoma Biotherapeutics, Inc.

1 program

Phase 1K

Kymera Therapeutics, Inc.

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

4 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

69 of 90 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody1820%Protein / enzyme11%Peptide11%Cell therapy11%

Small molecule leads; the ring shows all 90 classified programs, each share of the total. Modality classified for 97% of 101 pipeline programs.

Analysis

Trial Status

136

clinical trials

Completed62 · 46%
Recruiting27 · 20%
Active, not recruiting14 · 10%
Terminated10 · 7%
Withdrawn9 · 7%
Not yet recruiting9 · 7%
Other5 · 4%

Clinical Trials

Trial Activity

136 trials

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Recruiting·NNavigator Medicines, Inc.·Phase 2·NCT07384975·150 enrolled
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Recruiting·Novartis logoNovartis·N/A·NCT07243782·76 enrolled
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Recruiting·Novartis logoNovartis·Phase 3·NCT06840392·555 enrolled
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Recruiting·PPeking Union Medical College·N/A·NCT07109765·50 enrolled
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
Recruiting·MMoonLake Immunotherapeutics AG·Phase 3·NCT06768671·35 enrolled
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06707246·60 enrolled
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
Recruiting·VVirginia Clinical Research, Inc.·Phase 1·NCT06645821·15 enrolled
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Recruiting·UUniversity of Minnesota·Phase 1·NCT06058520·16 enrolled
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Recruiting·MMilton S. Hershey Medical Center·Phase 2·NCT04414514·24 enrolled
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Recruiting·Sanofi logoSanofi·Phase 2·NCT07170917·208 enrolled
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Recruiting·Takeda logoTakeda·Phase 2·NCT07244263·90 enrolled
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT06326476·12 enrolled
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Recruiting·Novartis logoNovartis·Phase 3·NCT06799000·555 enrolled
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06524635·60 enrolled
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Recruiting·AbbVie logoAbbVie·Phase 3·NCT05889182·1,328 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)